Relapsing-remitting multiple sclerosis therapy of Interferon-β Betaferon or Rebif: peripheral mononuclear blood cells
Summary:
Temporal analysis of PBMCs from relapsing-remitting multiple sclerosis (RRMS) patients treated with Interferon-β-1b (Betaferon) or IFNβ-1a (Rebif). Half of the patients developed neutralizing antibodies (NAB) to IFNβ. Results provide insight into molecular basis of IFNβ bioactivity in MS patient
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Malhotra S, Bustamante MF, Pérez-Miralles F, Rio J et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One 2011;6(8):e23634. PMID: 21886806
